In the typically-slow month of August, nine IPOs raised $1.0 billion, joined by 31 SPACs. Only four of the nine offerings raised over $100 million. Activity was well below August 2020, which saw investors and bankers skip their vacations due to the pandemic....read more
After a busy July, the IPO market began to pump the brakes this past week with four IPOs and four postponements. SPAC activity remained steady with seven blank check IPOs. New filers trickled into the IPO pipeline, with only one IPO and six SPACs submitting...read more
Adagio Therapeutics, a Phase 2/3 biotech developing antibody therapies to treat and prevent COVID-19, raised $309 million by offering 18.2 million shares at $17, within the range of $16 to $18. The company offered 0.5 million more shares than anticipated. ...read more
Adagio Therapeutics, a Phase 2/3 biotech developing antibody therapies for COVID-19 and other infectious diseases, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $301 million by offering 17.7 million shares at a price...read more
Renaissance Capital’s August IPO Market Update
In the typically-slow month of August, nine IPOs raised $1.0 billion, joined by 31 SPACs. Only four of the nine offerings raised over $100 million. Activity was well below August 2020, which saw investors and bankers skip their vacations due to the pandemic....read more
US IPO Weekly Recap: Postponements abound in a 4 IPO week
After a busy July, the IPO market began to pump the brakes this past week with four IPOs and four postponements. SPAC activity remained steady with seven blank check IPOs. New filers trickled into the IPO pipeline, with only one IPO and six SPACs submitting...read more
COVID-19 antibody biotech Adagio Therapeutics prices upsized IPO at $17 midpoint
Adagio Therapeutics, a Phase 2/3 biotech developing antibody therapies to treat and prevent COVID-19, raised $309 million by offering 18.2 million shares at $17, within the range of $16 to $18. The company offered 0.5 million more shares than anticipated. ...read more
COVID-19 antibody biotech Adagio Therapeutics sets terms for $301 million IPO
Adagio Therapeutics, a Phase 2/3 biotech developing antibody therapies for COVID-19 and other infectious diseases, announced terms for its IPO on Monday. The Waltham, MA-based company plans to raise $301 million by offering 17.7 million shares at a price...read more